Mereo BioPharma Group plc Holding(s) in Company (3005P)
2020年6月8日 - 11:20PM
ＲＮＳを含む英国規制内ニュース （英語）
TIDMMPH
RNS Number : 3005P
Mereo BioPharma Group plc
08 June 2020
TR-1: S tandard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and
to the FCA in Microsoft Word format if possible) (i)
1a. Identity of the issuer or the Mereo BioPharma Group plc
underlying issuer of existing shares
to which voting rights are attached
(ii) :
--------------------------------------------
1b. Please indicate if the issuer is a non-UK issuer (please mark with
an "X" if appropriate)
Non-UK issuer
----
2. Reason for the notification (please mark the appropriate box or boxes
with an "X")
An acquisition or disposal of voting rights X
----
An acquisition or disposal of financial instruments X
----
An event changing the breakdown of voting rights N/A
----
Other (please specify)(iii) : N/A
----
3. Details of person subject to the notification obligation (iv)
Name Baker Bros. Advisors LP
City and country of registered office New York, New York USA
(if applicable)
4. Full name of shareholder(s) (if different from 3.) (v)
Name Baker Brothers Life Sciences, L.P.
and 667, L.P.
--------------------------------------------
City and country of registered office Delaware USA
(if applicable)
--------------------------------------------
5. Date on which the threshold was 03/06/2020
crossed or reached (vi) :
--------------------------------------------
6. Date on which issuer notified (DD/MM/YYYY): 05/06/2020
--------------------------------------------
7. Total positions of person(s) subject to the notification obligation
% of voting % of voting rights Total of both Total number
rights attached through financial in % (8.A + of voting rights
to shares (total instruments 8.B) of issuer (vii)
of 8. A) (total of 8.B
1 + 8.B 2)
------------------ --------------------- -------------- --------------------
Resulting situation
on the date
on which threshold
was crossed
or reached 9.39% 0% 9.39% 213,652,487
------------------ --------------------- -------------- --------------------
Position of N/A N/A N/A
previous notification
(if
applicable)
------------------ --------------------- -------------- --------------------
8. Notified details of the resulting situation on the date on which
the threshold was crossed or reached (viii)
A: Voting rights attached to shares
Class/type of Number of voting rights % of voting rights
shares (ix)
ISIN code (if
possible)
Direct Indirect Direct Indirect
(Art 9 of Directive (Art 10 of Directive (Art 9 of Directive (Art 10 of Directive
2004/109/EC) 2004/109/EC) 2004/109/EC) (DTR5.1) 2004/109/EC)
(DTR5.1) (DTR5.2.1) (DTR5.2.1)
-----------------------------
GB00BZ4G2K23 20,061,437 9.39%
---------------------- ----------------------------- ------------------------- ---------------------
SUBTOTAL 8. A 20,061,437 9.39%
----------------------------------------------------- ------------------------------------------------
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC
(DTR5.3.1.1 (a))
Type of Expiration Exercise/ Number of voting % of voting
financial date Conversion Period rights that may rights
instrument (x) (xi) be acquired if
the instrument
is
exercised/converted.
----------- ---------------------------------- ------------------------------- ---------------------
Not convertible
until the underlying
shares are authorized
CONVERTIBLE NOTE by a shareholder
10% 6/2023 6/2023 vote 0 0%
----------- ---------------------------------- ------------------------------- ---------------------
Not exercisable
until the underlying
Warrants @ GBP shares are authorized
0.348 Expiring by a shareholder
8/8/2025 8/8/2025 vote 0 0%
----------- ---------------------------------- ------------------------------- ---------------------
SUBTOTAL 8. B 1 0 0%
---------------------------------- ------------------------------- ---------------------
B 2: Financial Instruments with similar economic effect according to
Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of Expiration Exercise/ Physical or Number of % of voting
financial date (x) Conversion cash voting rights rights
instrument Period (xi) settlement
(xii)
---------------- ---------------------- --------------------- --------------------
SUBTOTAL 8.B.2 N/A N/A
--------------------- --------------------
9. Information in relation to the person subject to the notification
obligation (please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled
by any natural person or legal entity and does not control any other
undertaking(s) holding directly or indirectly an interest in the
(underlying) issuer (xiii)
Full chain of controlled undertakings through which the voting rights X
and/or the
financial instruments are effectively held starting with the ultimate
controlling natural person or legal entity (xiv) (please add additional
rows as necessary)
Name (xv) % of voting rights % of voting rights Total of both if
if it equals or through financial it equals or is
is higher than the instruments if it higher than the
notifiable threshold equals or is higher notifiable threshold
than the notifiable
threshold
---------------------- --------------------- ------------------------
Baker Bros. Advisors
(GP) LLC 9.39% 0.0% 9.39%
---------------------- --------------------- ------------------------
Baker Bros. Advisors
LP 9.39% 0.0% 9.39%
---------------------- --------------------- ------------------------
Baker Brothers Life
Sciences, L.P. 8.71% 0.0% 8.71%
---------------------- --------------------- ------------------------
10. In case of proxy voting, please identify:
Name of the proxy holder N/A
-----------------------------------------------
The number and % of voting rights
held
-----------------------------------------------
The date until which the voting rights
will be held
-----------------------------------------------
11. Additional information (xvi)
Baker Bros. Advisors LP (the "Adviser") is the investment adviser of
Baker Brothers Life Sciences, L.P., and 667, L.P. (collectively, the
"Funds") and, pursuant to management agreements between the Adviser,
the Funds and the respective general partners of the Funds, has complete
and unlimited discretion and authority with respect to the Funds' investments
and voting power over investments.
Place of completion New York, New York USA
Date of completion June 5, 2020
-----------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
HOLFPMITMTBMBLM
(END) Dow Jones Newswires
June 08, 2020 10:20 ET (14:20 GMT)
Mereo Biopharma (LSE:MPH)
過去 株価チャート
から 12 2024 まで 1 2025
Mereo Biopharma (LSE:MPH)
過去 株価チャート
から 1 2024 まで 1 2025
Real-Time news about Mereo Biopharma Group Plc (ロンドン証券取引所): 0 recent articles
その他のMereo Biopharma Group Plcニュース記事